AIM AIM ImmunoTech

AIM ImmunoTech Announces IRB Approval to Enroll COVID-19 ‘Long Haulers’ in the AMP-511 ME/CFS Clinical Trial of Ampligen

AIM ImmunoTech Announces IRB Approval to Enroll COVID-19 ‘Long Haulers’ in the AMP-511 ME/CFS Clinical Trial of Ampligen
EN
06/10/2020

Underlying

AIMAIM ImmunoTech

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM ImmunoTech

 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Recent Presentation on the Potential of Priva...

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies OCALA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced a presentation and discussion on immunotherapies involving AIM’s drug Ampligen at the recent , held June 17–20, 2025, across Silicon Valley, San Francisco and Stanford University. Pawel Kalinski, MD, PhD, a world-renowned research oncologist, presented on the drug and participated in a discussion session titled Revolution in Healthcare. Dr. Kalins...

July 2, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Mi...

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (NYSE American: AIM) today announced the receipt of a warning notification (the “Letter”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the minimu...

June 20, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Resumes Trading on NYSE American

AIM ImmunoTech Resumes Trading on NYSE American Company trading under the ticker “AIM” NYSE American effective at the start of trading today, Tuesday, June 17th OCALA, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced that its common stock has resumed trading on the NYSE American under the symbol "AIM" and CUSIP 00901B303, effective at the start of trading today, June 17, 2025. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of ...

June 17, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing T...

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen® Patent portfolio now includes protection for manufacture, methods and compositions Provides AIM with patent protection for manufacturing Ampligen until 2041 OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (OTC Pink: AIMID) (“AIM” or the “Company”) today announced the United States Patent and Trademark Office has granted U.S. patent No. 12312376, titled “Therapeutic Double Stranded RNA and Methods for Producing the Same.” The patent expires January 25, 2041. T...

June 12, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025 OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE) -- (OTC Pink: AIMID) (NYSE American: AIM) (“AIM” or the “Company”) today announced that the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspension of the Company's common stock on the NYSE American. The NYSE Regulation staff determined that the Company's common stock was now trading above the threshold of low selling price issues as further...

June 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch